Literature DB >> 33472614

miR-636 inhibits EMT, cell proliferation and cell cycle of ovarian cancer by directly targeting transcription factor Gli2 involved in Hedgehog pathway.

Jiong Ma1, Chunxia Zhou1, Xuejun Chen2.   

Abstract

BACKGROUND: Hedgehog (Hh) signaling pathway, which is essential for cell proliferation and differentiation, is noted to be aberrantly activated in tumor from increasing studies in recent years. MicroRNAs (miRNAs) as an important non-coding RNA in cells have been proven to possess a regulatory role specific to the Hh signaling pathway. Here, in vitro and in vivo cellular/molecular experiments were adopted to clarify the regulatory mechanism linking miR-636 to the Hh signaling pathway in ovarian cancer (OVC).
METHODS: Protein-protein interaction analysis was performed to identify the hub gene in the Hh pathway. TargetScan database was used to predict the potential upstream regulators for Gli2. qRT-PCR was performed to test the expression of miR-636, while Western blot was conducted to detect the expression of proteins related to the Hh pathway and epithelial-mesenchymal transition (EMT). For cell functional experiments, HO-8910PM OVC cell line was used. MTT assay and wound healing assay were used to measure the effect of miR-636 on cell proliferation and migration. Flow cytometry was carried out to examine the effect of miR-636 on cell cycle, and Western blot was used to identify the change in expression of Hh and EMT-related proteins. Dual-luciferase reporter gene assay was implemented to detect the targeting relationship between miR-636 and Gli2. Xenotransplantation models were established for in vivo examination.
RESULTS: Gli2 was identified as the hub gene of the Hh pathway and it was validated to be regulated by miR-636 based on the data from TargetScan and GEO databases. In vitro experiments discovered that miR-636 was significantly lowly expressed in OVC cell lines, and overexpressing miR-636 significantly inhibited HO-8910PM cell proliferation, migration and induced cell cycle arrest in G0/G1 phase, while the inhibition of miR-636 caused opposite results. Dual-luciferase reporter gene assay revealed that Gli2 was the target gene of miR-636 in OVC. Besides, overexpressed miR-636 decreased protein expression of Gli2, and affected the expression of proteins related to the Hh signaling pathway and EMT. Rescue experiments verified that overexpression of Gli2 reversed the inhibitory effect of miR-636 on HO-8910PM cell proliferation and migration, and attenuated the blocking effect of miR-636 on cell cycle. The xenotransplantation experiment suggested that miR-636 inhibited cell growth of OVC by decreasing Gli2 expression. Besides, overexpressing Gli2 potentiated the EMT process of OVC cells via decreasing E-cadherin protein expression and increasing Vimentin protein expression, and it reversed the inhibitory effect of miR-636 on OVC cell proliferation in vivo.
CONCLUSION: miR-636 mediates the activation of the Hh pathway via binding to Gli2, thus inhibiting EMT, suppressing cell proliferation and migration of OVC. TRIAL REGISTRATION: The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of The Second Affiliated hospital of Zhejiang University School of Medicine (IR2019001235). Written informed consent was obtained from individual or guardian participants.

Entities:  

Keywords:  Gli2; Migration; Ovarian cancer; Proliferation; miR-636

Year:  2021        PMID: 33472614      PMCID: PMC7819188          DOI: 10.1186/s12935-020-01725-7

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  42 in total

1.  miR-26a and miR-26b inhibit esophageal squamous cancer cell proliferation through suppression of c-MYC pathway.

Authors:  Juan Li; Yue Liang; Hao Lv; Hui Meng; Gang Xiong; Xingying Guan; Xuedan Chen; Yun Bai; Kai Wang
Journal:  Gene       Date:  2017-05-03       Impact factor: 3.688

2.  GLI2-Mediated Inflammation in the Tumor Microenvironment.

Authors:  Weiguo Han; Shereen A Allam; Sherine F Elsawa
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  lncRNA SNHG1 cooperated with miR-497/miR-195-5p to modify epithelial-mesenchymal transition underlying colorectal cancer exacerbation.

Authors:  Jinghui Bai; Jian Xu; Jian Zhao; Rui Zhang
Journal:  J Cell Physiol       Date:  2019-07-05       Impact factor: 6.384

4.  Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer.

Authors:  Yen-An Tang; Yu-Feng Chen; Yi Bao; Sylvia Mahara; Siti Maryam J M Yatim; Gokce Oguz; Puay Leng Lee; Min Feng; Yu Cai; Ern Yu Tan; Sau Shung Fong; Zi-Huan Yang; Ping Lan; Xiao-Jian Wu; Qiang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-11       Impact factor: 11.205

Review 5.  The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.

Authors:  Priya Samuel; David Raul Francisco Carter
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

6.  Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer.

Authors:  Christina R Adams; Htet Htwe Htwe; Timothy Marsh; Aprilgate L Wang; Megan L Montoya; Lakshmipriya Subbaraj; Aaron D Tward; Nabeel Bardeesy; Rushika M Perera
Journal:  Elife       Date:  2019-05-28       Impact factor: 8.140

7.  Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death.

Authors:  Naoshad Muhammad; Robert Steele; T Scott Isbell; Nancy Philips; Ratna B Ray
Journal:  Oncotarget       Date:  2017-08-03

Review 8.  Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.

Authors:  Bowen Du; Joong Sup Shim
Journal:  Molecules       Date:  2016-07-22       Impact factor: 4.411

9.  GLI2 promotes cell proliferation and migration through transcriptional activation of ARHGEF16 in human glioma cells.

Authors:  Dengliang Huang; Yiting Wang; Linlin Xu; Limin Chen; Minzhang Cheng; Wei Shi; Huanting Xiong; Detina Zalli; Shiwen Luo
Journal:  J Exp Clin Cancer Res       Date:  2018-10-11

10.  MiR-454-3p and miR-374b-5p suppress migration and invasion of bladder cancer cells through targetting ZEB2.

Authors:  Suogang Wang; Geng Zhang; Wanxiang Zheng; Qin Xue; Di Wei; Yu Zheng; Jianlin Yuan
Journal:  Biosci Rep       Date:  2018-12-07       Impact factor: 3.840

View more
  6 in total

1.  Circ_0025039 acts an oncogenic role in the progression of non-small cell lung cancer through miR-636-dependent regulation of CORO1C.

Authors:  Lei Wang; Cimei Zeng; Zhongren Chen; Jianxu Qi; Sini Huang; Haimei Liang; Shiren Huang; Zongxing Ou
Journal:  Mol Cell Biochem       Date:  2022-01-16       Impact factor: 3.396

2.  Activation of the hedgehog signaling pathway is associated with the promotion of cell proliferation and epithelial-mesenchymal transition in chronic rhinosinusitis with nasal polyps.

Authors:  Yankun Wang; Xiuwei Wang; Mulan Jin; Jun Lu
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-10-03       Impact factor: 3.236

Review 3.  Noncoding RNAs related to the hedgehog pathway in cancer: clinical implications and future perspectives.

Authors:  Jia Song; Yuexin Ge; Xiaoyu Sun; Qiutong Guan; Shiqiang Gong; Minjie Wei; Jumin Niu; Lin Zhao
Journal:  Mol Cancer       Date:  2022-05-17       Impact factor: 41.444

4.  Circ_0010235 facilitates lung cancer development and immune escape by regulating miR-636/PDL1 axis.

Authors:  Jixing Zhao; Wu Yan; Wencong Huang; Yongsheng Li
Journal:  Thorac Cancer       Date:  2022-02-15       Impact factor: 3.500

Review 5.  Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.

Authors:  Daniel L Pouliquen; Alice Boissard; Cécile Henry; Olivier Coqueret; Catherine Guette
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

6.  Identification of Novel miRNAs, Targeting Genes, Signaling Pathway, and the Small Molecule for Overcoming Oxaliplatin Resistance of Metastatic Colorectal Cancer.

Authors:  Md Misbah; Manoj Kumar; Kuen-Huar Lee; Shing-Chuan Shen
Journal:  Biomed Res Int       Date:  2022-09-19       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.